CorMedix Set for Breakout with DefenCath's Outpatient Launch
AI Prediction of CorMedix Inc. (CRMD)
CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products, shows promise with its lead product, DefenCath. Recent FDA approval and subsequent commercial launch plans indicate potential growth. The upcoming PDUFA date and commercial roll-out in outpatient settings could serve as significant catalysts, impacting the stock positively.
CRMD Report Information
Prediction Date2025-07-03
Close @ Prediction$11.62
Mkt Cap573m
IPO Date2010-05-13
AI-derived Information
Recent News for CRMD
- Feb 12 — CorMedix to Participate in Upcoming Investor Conferences (GlobeNewswire)
- Feb 11 — CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback (Insider Monkey)
- Feb 11 — CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside (Zacks)
- Feb 10 — CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead (MarketBeat)
- Feb 2 — CorMedix Therapeutics Announces Share Repurchase Program (GlobeNewswire)
- Jan 31 — H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance (Insider Monkey)
- Jan 30 — CRMD Down 31% in a Month: Is This an Indication to Sell the Stock? (Zacks)
- Jan 29 — CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 (GlobeNewswire)
- Jan 23 — Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? (Zacks)
- Jan 20 — CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.